Palatin Technologies Raises $340K in Private Placement

Palatin Technologies ( (PTNT) ) has shared an announcement.

On June 10, 2025, Palatin Technologies entered into a securities purchase agreement with accredited investors to sell Series D Convertible Preferred Stock and Series I common stock purchase warrants in a private placement, closing on June 13, 2025, raising $340,000 for working capital. The Preferred Stock, convertible into common stock, and warrants were sold at $0.11 per share, with key company executives participating as purchasers. The company plans to file a registration statement for resale of shares and warrants, impacting its financial strategy and shareholder structure.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.

Spark’s Take on PTNT Stock

According to Spark, TipRanks’ AI Analyst, PTNT is a Neutral.

Palatin Technologies faces significant financial difficulties, with persistent losses and negative equity impacting its financial health. The technical analysis indicates weak momentum, with prices well below critical moving averages. The valuation is poor due to a negative P/E ratio and lack of dividend yield. These factors contribute to a low overall stock score, highlighting the need for substantial improvements in financial performance and market positioning.

To see Spark’s full report on PTNT stock, click here.

More about Palatin Technologies

Palatin Technologies, Inc. operates in the biotechnology industry, focusing on developing targeted receptor-specific therapeutics for the treatment of diseases with significant unmet medical needs. The company’s primary products include therapies for sexual dysfunction, inflammatory diseases, and other conditions.

Average Trading Volume: 2,650,468

Technical Sentiment Signal: Sell

Current Market Cap: $4.88M

For an in-depth examination of PTNT stock, go to TipRanks’ Overview page.